Synthesis of stable benzimidazole derivatives bearing pyrazole as anticancer and EGFR receptor inhibitors

被引:73
作者
Akhtar, Md. Jawaid [1 ]
Khan, Ahsan Ahmed [1 ]
Ali, Zulphikar [1 ]
Dewangan, Rikeshwer Prasad [2 ]
Rafi, Md. [1 ]
Hassan, Md. Quamrul [3 ]
Akhtar, Md. Sayeed [3 ]
Siddiqui, Anees Ahmad [1 ]
Partap, Sangh [1 ]
Pasha, Santosh [2 ]
Yar, M. Shahar [1 ]
机构
[1] Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmaceut Chem, New Delhi 110062, India
[2] Inst Genom & Integrat Biol, Lab 405, New Delhi, India
[3] Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmacol, New Delhi 110062, India
关键词
Benzimidazole linked pyrazole; Anticancer; Apoptosis; Docking studies; Cardiomyopathy studies; TYROSINE KINASE INHIBITORS; GROWTH-FACTOR RECEPTOR; BIOLOGICAL EVALUATION; REVERSIBLE INHIBITOR; CYTOTOXIC AGENTS; DUAL INHIBITORS; TK INHIBITORS; DNA-BINDING; DESIGN; CANCER;
D O I
10.1016/j.bioorg.2018.03.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A new series of benzimidazole linked pyrazole derivatives were synthesized by cyclocondensation reaction through one-pot multicomponent reaction in absolute ethanol. All the synthesized compounds were tested for their in vitro anticancer activities on five human cancer cell lines including MCF-7, HaCaT, MDA-MB231, A549 and HepG2. EGFR receptor inhibitory activities were carried out for all the compounds. Majority of the compounds showed potent antiproliferative activity against the tested cancer cell lines. Compound 5a showed the most effective activity against the lungs cancer cell lines (IC50 = 2.2 mu M) and EGFR binding (IC50 = 0.97 mu M) affinity as compared to other members of the series. Compound 5a inhibited growth of A549 cancer cells by inducing a strong G(2)/M phase arrest. In addition, same compound inhibited growth of A549 cancer cells by inducing apoptosis. In molecular docking studies compound 5a was bound to the active pocket of the EGFR (PDB 1M17) with five key hydrogen bonds and two pi-pi interaction with binding energies Delta G = -34.581 Kcal/mol. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:158 / 169
页数:12
相关论文
共 41 条
  • [1] Design, synthesis and antitumor activity of novel pyrazolo[3,4-d]pyrimidine derivatives as EGFR-TK inhibitors
    Abdelgawad, Mohamed A.
    Bakr, Rania B.
    Alkhoja, Olla A.
    Mohamed, Wafaa R.
    [J]. BIOORGANIC CHEMISTRY, 2016, 66 : 88 - 96
  • [2] Design, synthesis, docking and QSAR study of substituted benzimidazole linked oxadiazole as cytotoxic agents, EGFR and erbB2 receptor inhibitors
    Akhtar, Md Jawaid
    Siddiqui, Anees Ahmad
    Khan, Ahsan Ahmed
    Ali, Zulphikar
    Dewangan, Rikeshwer Prasad
    Pasha, Santosh
    Yar, M. Shahar
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 126 : 853 - 869
  • [3] Identification of new potent phthalazine derivatives with VEGFR-2 and EGFR kinase inhibitory activity
    Amin, Kamilia M.
    Barsoum, Flora F.
    Awadallah, Fadi M.
    Mohamed, Nehal E.
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 123 : 191 - 201
  • [4] Synthesis and biological evaluation of novel coumarin-pyrazoline hybrids endowed with phenylsulfonyl moiety as antitumor agents
    Amin, Kamilia M.
    Eissa, Amal A. M.
    Abou-Seri, Sahar M.
    Awadallah, Fadi M.
    Hassan, Ghaneya S.
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2013, 60 : 187 - 198
  • [5] [Anonymous], 2014, HUMAN EPIDERMAL GROW, P1
  • [6] Bakr RB, 2012, B PHARM SCI, V35, P27
  • [7] 5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase
    Ballard, P
    Bradbury, RH
    Hennequin, LFA
    Hickinson, DM
    Johnson, PD
    Kettle, JG
    Klinowska, T
    Morgentin, R
    Ogilvie, DJ
    Olivier, A
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (19) : 4226 - 4229
  • [8] Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors
    Barlaam, Bernard
    Anderton, Judith
    Ballard, Peter
    Bradbury, Robert H.
    Hennequin, Laurent F. A.
    Hickinson, D. Mark
    Kettle, Jason G.
    Kirk, George
    Klinowska, Teresa
    Lambert-Van der Brempt, Christine
    Trigwell, Cath
    Vincent, John
    Ogilvie, Donald
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (08): : 742 - 746
  • [9] Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors
    Breccia, Massimo
    Alimena, Giuliana
    [J]. LEUKEMIA RESEARCH, 2013, 37 (06) : 713 - 720
  • [10] 2-Phenyl-5-(pyrrolidin-1-yl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazole, a benzimidazole derivative, inhibits growth of human prostate cancer cells by affecting tubulin and c-Jun N-terminal kinase
    Chang, Wei-Ling
    Chang, Chih-Shiang
    Chiang, Po-Cheng
    Ho, Yunn-Fang
    Liu, Ju-Fang
    Chang, Kai-Wei
    Guh, Jih-Hwa
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2010, 160 (07) : 1677 - 1689